Market Analysis: Global Neuroendocrine Tumors Market
Neuroendocrine tumors market is rise gradually to an estimated value of USD 2.80 Billion by 2026 registering a CAGR of 10.2% in the forecast period of 2019-2026. Increasing prevalence of neuroendocrine tumors and accelerating demand of clinical treatment and novel therapies indicates the significant growth of market.
Global Neuroendocrine Tumors Market By Site of Origin (Carcinoid tumors in the lungs, Pancreatic neuroendocrine tumors, Medullary thyroid carcinoma, Merkel cell carcinoma, Pheochromocytoma of the adrenal gland, Small cell lung cancer, Large cell lung cancer and others), Therapy Type (Chemotherapy, Hormonal therapy, Immunotherapy, Surgery, Medication and Others), Mechanism of action Type (Somatostatin analogs, Tyrosine Kinase Inhibitor, Peptide receptor radionuclide, Alfa-interferon, Proton-pump inhibitors and Others), Drug Type (Everolimus, Sunitinib malate, Lorlatinib, Nivolumab, Dacomitinib, Brigatinib, Durvalumab, Atezolizumab, Alectinib, Crizotinib, Topotecan hydrochloride, Bevacizumab and Others), End- users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026
Get More Insights About Global Neuroendocrine Tumors Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-neuroendocrine-tumors-market
Market Definition: Global Neuroendocrine Tumors Market
Neuroendocrine tumors are an oncology disorder in which cancer arises from neuroendocrine cells and proliferate almost all over the body. The organs affected by neuroendocrine tumors are mainly, gastrointestinal (GI) tract, gallbladder, pancreas, lungs and thyroid. It is seen rarely in thymus, kidneys, liver, prostate, skin and ovaries. The patient may experience indigestion, abdominal pain, difficulty in breathing, muscle weakness, jaundice, weight loss etc.
According to the statistics published in American Society of Clinical Oncology, the total prevalent population of neuroendocrine tumors in United States was over 170,000, it is estimated that 12,000 new cases of patients in United States diagnosed with neuroendocrine tumors each year.
Market Drivers
· Increase in prevalence rate of neuroendocrine tumor in geriatric population worldwide
· Accelerating demand of treatment and novel therapies
· Rising awareness about treatment and technological advancement is driving the growth of market
Market Restraints
· Effective treatment is either unavailable or unaffordable
· Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
· Lack of awareness about novel therapies and clinical development for neuroendocrine tumors
Know more about this report https://www.databridgemarketresearch.com/reports/global-neuroendocrine-tumors-market
Competitive Analysis: Global Neuroendocrine Tumors Market
Global neuroendocrine tumors market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of neuroendocrine tumors market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa
Key Market Players: Global Neuroendocrine Tumors Market
Few of the major competitors currently working in the global neuroendocrine tumors market are, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Amgen, Inc., Ipsen Pharma, GlaxoSmithKline Plc, Regeneron Pharmaceuticals, Mylan N.V, Sanofi S.A, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Advanced Accelerator Applications and among others
Get Access to full Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-neuroendocrine-tumors-market
Research Methodology: Global Neuroendocrine Tumors Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.
The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request Detailed TOC@ https://www.databridgemarketresearch.com/toc/?dbmr=global-neuroendocrine-tumors-market
Key Developments in the Market:
In January 2018, Advanced Accelerator Applications received FDA approval for Lutathera (lutetium Lu 177 dotatate), a radioactive somatostatin receptor acting as a Peptide Receptor Radionuclide Therapy (PRRT), indicated for the treatment of adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previously, drug also received Orphan Drug designation by both the US FDA and European Medicines Agency (EMA)
In April 2019, Merck & Co., Inc received expanded approval from the US FDA for Keytruda (pembrolizumab), an anti-PD-1 therapy as a first line treatment of patients with stage III non-small cell lung cancer
Reasons to Purchase this Report
· Current and future of global neuroendocrine tumors market outlook in the developed and emerging markets
· The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
· Regions/Countries that are expected to witness the fastest growth rates during the forecast period
· The latest developments, market shares, and strategies that are employed by the major market players
Customization of the Report:
· All segmentation provided above in this report is represented at country level
· All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)
Browse Trending Related Reports @
· Contraceptive Devices Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Tel: +1-888-387-2818
Email: [email protected]
